Evidence map›Paper›PMID 36423057›Full record

ArticleVaccines2022

Differential Cell Line Susceptibility to the SARS-CoV-2 Omicron BA.1.1 Variant of Concern.

Hitesh Dighe, Prasad Sarkale, Deepak Y Patil, Sreelekshmy Mohandas, Anita M Shete, Rima R Sahay, Rajen Lakra, Savita Patil, Triparna Majumdar, Pranita Gawande and 3 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Hitesh DigheIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.ORCID 0000-0003-1306-1550
Prasad SarkaleIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Deepak Y PatilIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Sreelekshmy MohandasIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Anita M SheteIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Rima R SahayIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Rajen LakraIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Savita PatilIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Triparna MajumdarIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Pranita GawandeIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Jyoti YemulIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Pratiksha VedpathakIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
Pragya D YadavIndian Council of Medical Research-National Institute of Virology, Pune 411021, Maharashtra, India.
ICMR-National Institute of Virology · IN

Funding

National Institute of Virology MCL2021
6 · The paper itself

Abstract

The unique mutations of the SARS-CoV-2 Omicron variant are associated with increased transmissibility, immune escape, increased binding affinity to ACE-2, and increased viral load. Omicron exhibited a shift in tropism infecting the upper respiratory tract compared to other variants of concern which have tropism for the lower respiratory tract. The tropism of omicron variants in cell lines of different hosts and tissue origins still remains unclear. Considering this, we assessed the susceptibility of different cell lines to the SARS-CoV-2 omicron BA.1.1 variant and permissiveness among different cell lines for omicron replication. Susceptibility and permissiveness of a total of eleven cell lines, including six animal cell lines and five human cell lines for omicron BA.1.1 infection, were evaluated by infecting individual cell lines with omicron BA.1.1 isolate at a 0.1 multiplicity of infection. Virus replication was assessed by observation of cytopathic effects followed by viral load determination by real-time PCR assay and virus infectivity determination by TCID50 assay. The characteristic cytopathic effect, increased viral load, and productive omicron replication was detected in Vero CCL-81, Vero E6, Vero/hSLAM, MA-104, and Calu-3 cells. Although LLC MK-2 cells showed an increased TCID50 titer at the second infection, the viral load did not show much difference in both infections. Caco-2 cells did not show evident CPE, but they supported omicron replication at a low level. A549, RD, MRC-5, and BHK-21 cells supported omicron BA.1.1 replication without the CPE. This is the first study on the comparison of susceptibility of different cell lines to Omicron variant BA.1.1, which might be useful for future studies on emerging SARS-CoV-2 variants.

Indexed as

cell susceptibilitycytopathic effectomicronSARS-CoV-2virus replication

Identifiers

PMID36423057
PMCPMC9696227
OpenAlexW4309736108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.